Spero sought approval of tebipenem on the strength of a phase 3 trial – ADAPT-PO – which showed that the drug was equivalent to standard care with intravenous ertapenem in patients with cUTI ...

gmail.com Background Acute pyelonephritis in children may result in permanent ... administered by either route (oral or intravenous). We excluded studies not having a control group or not reporting ...

The Massachusetts-based biotech sought approval of tebipenem on the strength of a phase 3 trial – called ADAPT-PO – which showed that the drug was equivalent to standard care with intravenous ...

Endoscopy was performed with local anaesthetic throat spray and all patients were offered conscious sedation with intravenous midazolam 1 ... participant passed away due to sepsis secondary to acute ...

An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-Spectrum β-lactamase-phenotype Gram ...

The challenges of translating neuroprotective interventions with promising efficacy in animal studies into effective treatments for patients with stroke are well documented, with issues including ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

Alcohol use disorder is a prevalent and major but preventable cause of morbidity and mortality worldwide, causing several ...

Fluoroquinolones are the most frequently recommended option for complicated cystitis and pyelonephritis. Guideline recommendations for recurrent UTI include antibiotic prophylaxis and treatment.

Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is ...